Product Center
Launch Meeting of Post-Marketing Safety Evaluation Study for Tetravalent Influenza Virus Subunit Vaccine Concludes Successfully
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25
- Views:
(Summary description)Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
Launch Meeting of Post-Marketing Safety Evaluation Study for Tetravalent Influenza Virus Subunit Vaccine Concludes Successfully
(Summary description)Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25 14:16
- Views:
Recently, the kickoff meeting for Ab&B Bio-Tech Co., Ltd. JS's post-marketing safety evaluation study of its tetravalent influenza virus subunit vaccine was successfully held in Lanzhou, Gansu Province.
This multicenter study is led by the Jiangsu Provincial Center for Disease Control and Prevention, under the guidance of the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring, and jointly conducted by six provincial CDCs, aiming to evaluate the safety profile of the tetravalent influenza virus subunit vaccine in an expanded population aged 3 years and above, enhance the post-marketing safety monitoring framework for vaccines in China, establish a long-term active surveillance mechanism, and advance the vaccine regulatory system toward higher maturity levels.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
